Table 5.
Risk groups for biochemical recurrence of localised and locally advanced prostate cancer, as introduced in the joint guidelines of the European Association of Urology, the European Society for Radiotherapy & Oncology and the International Society of Geriatric Oncology 2016 [25].
| Low-Risk | Intermediate-Risk | High-Risk | |
|---|---|---|---|
| Definition | |||
| PSA <10 ng/mL | PSA 10–20 ng/mL | PSA > 20 ng/mL | any PSA |
| and GS <7 | or GS 7 | or GS >7 | any GS |
| and cT1-2a | or cT2b | or cT2c | cT3–4 or cN+ |
| Localised | Localised | Localised | Locally advanced |
GS: Gleason score; PSA: prostate-specific antigen.